• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A Review of Medications for PTSD, With a Focus on Topiramate

A Review of Medications for PTSD, With a Focus on Topiramate

May 4, 2021
Paul Riordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A new patient comes into your office for an assessment. He tells you he cannot keep living this way. He shops at Walmart at 3 am to avoid strangers. He startles easily and suffers from nightmares and flashbacks related to a trauma he experienced in the Army. He’s tried sertraline and venlafaxine for PTSD but did not find them helpful and wants to try something else. You offer a referral for trauma-focused therapy, but he refuses, saying “I don’t want to talk to anyone.”

Are there any other medications that could help? When it comes to PTSD, trauma-focused therapy is first-line. It is backed by solid data with a large effect size, while medications have only mild treatment effects (Lee DJ et al, Depress Anxiety 2016;33(9):792–806). A possible exception to this rule is that patients who choose their preferred treatment do better when they receive their choice—meaning patients who prefer pills do better when they get pills (Mergl R et al, Psychother Psychosom 2011;80(1):39–47).

Which medications work in PTSD?
Sertraline and paroxetine have FDA approval in PTSD, but there is nothing about the pathophysiology of PTSD that points to SSRIs as the cure. In some countries, SSRIs did not gain approval because they mainly worked in civilian trauma and not military trauma, but military trauma is more difficult to treat whether with medications or therapy. A new meta-analysis—the largest to date—compared effect sizes of 26 medications across 58 studies that had a total of nearly 7,000 patients with PTSD (de Moraes Costa G et al, J Psychiatr Res 2020;130:412–420).

What did the study find? Only seven medications—fluoxetine, paroxetine, quetiapine, risperidone, sertraline, topiramate, and venlafaxine—were better than placebo. Missing from this list is prazosin; it no longer passes statistical muster due to a large negative trial of 304 veterans with PTSD (Raskind MA et al, N Engl J Med 2018;378(6):507–517), but there were flaws with that study that lead some to believe prazosin does work in a subset of patients (see TCPR, April 2019).
Table: Seven Medications for PTSD

Table: Seven Medications for PTSD

(Click to view full-size PDF.)

As expected, the SSRIs and SNRIs had small benefits, with effect sizes ranging from 0.2 to 0.35—about the same as the small effect sizes observed for antidepressants in depression (Ormel J et al, Psychol Med 2019;50(2):177–186). Fluoxetine had the best balance of efficacy and acceptability, but that was mainly due to high tolerability, since its benefit was small. Despite the small effect sizes, our confidence in those benefits is high, with each medication having 650–1,400 total participants across their trials.

In contrast, the effect sizes were larger (0.5–0.6) for a few off-label medications: topiramate, risperidone, and quetiapine. However, there were only a few studies backing these medications, with only 70–100 patients each—so while they show promise, it’s not definite since small studies are notorious for inflated effect sizes.

Benefits of topiramate for PTSD
Most surprisingly, topiramate came out on top as having the greatest benefit for PTSD, with a medium effect size (0.57). There is a lot of uncertainty around that figure, as it was based on only two randomized trials involving 73 civilian patients. However, three randomized trials of 137 veterans were excluded because they focused on treatment-resistant PTSD (two studies) or on comorbid alcohol use disorder with PTSD symptoms as a secondary outcome (one study). If these studies are included, the total n becomes 210, with one positive trial, three trials trending toward significance, and one negative trial. The negative trial, which focused on treatment-resistant PTSD in veterans, had a high dropout rate due to side effects (Lindley SE et al, J Clin Psychopharmacol 2007;27(6):677–681). In the other trials, while topiramate caused side effects like dizziness, paresthesias, and memory problems, it did not lead to more dropouts.

What did topiramate help with? Across studies, it appeared most helpful for the “reexperiencing” symptoms—flashbacks, intrusive memories, and nightmares, with less benefit for avoidance and numbing symptoms.

Topiramate demonstrated other benefits relevant to PTSD. For example, in one trial, veterans with PTSD who took topiramate had 55% fewer standard drinks per week than those taking placebo (Batki SL et al, Alcohol Clin Exp Res 2014;38(8):2169–2177). Topiramate is also FDA approved for migraine prophylaxis and—based on small controlled trials—may help with obesity, borderline personality disorder, cocaine abuse, and impulse control disorders (Nourredine M et al, CNS Drugs 2021;35(2):177–213; Varghese BS et al, Indian J Pharmacol 2010;42(3):135–141). Unlike the antidepressants, it is safe in bipolar disorder.

How to use
Slow titration is recommended for topiramate’s FDA-approved indications (migraines and epilepsy), and we have found that strategy helpful in reducing side effects like dizziness and cognitive impairment. For PTSD, start at 25 mg nightly and raise by no more than 25 mg/week toward a target dose of 100–300 mg daily. With a 21-hour half-life, nightly dosing is acceptable, but opt for divided dosing if the patient experiences side effects as the level peaks.

The most common side effects to watch for are dizziness, paresthesias, somnolence, and cognitive impairment. For cognition, topiramate typically affects word finding and verbal fluency—tested by listing as many animals as possible in 60 seconds (Thompson PJ et al, J Neurol Neurosurg Psychiatry 2000;69(5):636–641). Rare side effects to watch for include kidney stones, glaucoma, increased body temperature, and metabolic acidosis.

TCPR Verdict: Topiramate has potential as second- or third-line pharmacology for PTSD after a trial of SSRIs/SNRIs, and it may be closer to first-line for patients with comorbid alcohol use disorder.


podcastsRelated Podcast Episode:
13 Ways to Use Topiramate
We ask the big questions: Is topiramate a drug or a sugar? Do you need to use the FDA-approved combo pill for weight loss? And which of its 13 off-label psychiatric uses are ready for clinical practice?


General Psychiatry
KEYWORDS ptsd
    Paul Riordan, MD.

    Should We Use Two Antidepressants to Treat Unipolar Depression?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 4, 2021
    SUBSCRIBE NOW
    Table Of Contents
    In Brief: Lamotrigine Gets a New Warning
    A Review of Medications for PTSD, With a Focus on Topiramate
    What’s Wrong With Generics?
    Depression, Vitamin D, and COVID-19
    Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?
    CME Post-Test - Problems with Generics, TCPR, May 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.